CPA
MGNX icon

Capital Performance Advisors’s MacroGenics MGNX Stock Holding History

Capital Performance Advisors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,462
Closed -$4.81K – 1653
2024
Q3 		$4.81K Buy
+1,462
New +$5.7K ﹤0.01% 1129

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Capital Performance Advisors's MGNX Position: Q4 2024 in Review

Capital Performance Advisors sold out of MacroGenics (MGNX) in Q4 2024, closing a stake of 1,462 shares — an estimated $4.81K sold.

Capital Performance Advisors first reported a position in MGNX in Q3 2024 and held it in 1 quarter. The position peaked at $4.81K in Q3 2024. 128 funds tracked by Wall St. Rank hold MGNX as of Q4 2024.

  • Capital Performance Advisors reported no remaining MacroGenics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1,462 MacroGenics shares in Q4 2024, an estimated $4.81K.
  • Capital Performance Advisors first reported a position in MacroGenics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's MacroGenics position peaked at $4.81K in Q3 2024.
  • 128 funds tracked by Wall St. Rank held MacroGenics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.